1. Igeneon
Raises $34,300,000 in Series C Round [Austria]
Igeneon is a developer of unique cancer vaccines against major
cancer types such as colorectal, gastric, and prostate cancer.
INVESTORS: 3i Group, Burrill & Company, Capexit, Deutsche
Venture Capital, gamma capital partners, Novartis Venture Fund
2/27/2004 11:53:15 AM
2. Diatos
Raises $8,880,000 in New Round [France]
Diatos is a developer of drug delivery solutions used in the treatment
of cancer and infectious diseases.
INVESTORS: Innoven Partners (Lead), Credit Lyonnais Private
Equity, GIMV, NIF Ventures
2/25/2004 11:50:36 AM
3. Aegera
Therapeutics Raises $15,000,000 in Third Round [Canada]
Aegera Therapeutics is a private North American biotechnology
company focused on exploiting apoptosis control to extend and
enhance the lives of cancer patients: killing cancer cells by
inducing apoptosis and rescuing neurons from apoptotic cell death.
INVESTORS: VenGrowth Capital (Lead), Business Development
Bank of Canada (BDC), Desjardins Venture Capital, Fondaction,
GeneChem Management, GrowthWorks Capital, Innovatech Grand Montreal,
Solidarity Fund QFL
2/24/2004 4:14:00 PM
4. Domantis
Raises $33,000,000 in Series B Round [Cambridge, MA]
Domantis is a developer of drugs with a focus on the smallest
antibody fragments called Domain Antibodies(dAbs).
INVESTORS: 3i Group (Lead), Albany Ventures, Gray Ghost,
MVM Limited
2/24/2004 12:27:25 PM
5. AlgoRx
Pharmaceuticals Raises $65,000,000 in Series C Round [Cranbury,
NJ]
AlgoRx Pharmaceuticals is a developer of pharmaceutical products
and technologies to address the large unsatisfied pain market.
INVESTORS: Advent International (Lead), Axiom Venture Partners,
Cogene Biotech Ventures, EGS Healthcare Capital Partners, Hunt
Ventures, Index Ventures, InterWest Partners, JPMorgan Partners,
Lehman Brothers Venture Partners, NIF Ventures, Pacific Rim Ventures,
P...
2/24/2004 12:07:15 PM
6. NeurogesX
Raises $35,000,000 in Series C Round [San Carlos, CA]
NeurogesX is a developer of therapeutic agents for the treatment
of nerve signaling disorders that result in a variety of disabling
conditions including pain.
INVESTORS: Global Life Science Ventures (Lead), Alta Partners,
ARCH Venture Partners, Diamond Capital, Montreux Equity Partners,
TIAA-CREF, University of North Carolina Endowment Fund, Walden
International
2/24/2004 11:33:00 AM
7. Chaperone
Technologies Raises Seed Financing Round [Wayne, PA]
Chaperone Tecnologies is a developer of antimicrobial products,
based on a novel and proprietary mechanism of action, for difficult-to-treat
and drug-resistant organisms across a broad range of infectious
diseases.
INVESTORS: Innovation Philadelphia
2/23/2004 3:37:04 PM
8. Y's
Therapeutics Raises $22,000,000 in Series B Round [Japan]
Y's Therapeutics is a privately held drug development biotechnology
company developing truly effective next-generation drugs with
a focus on antibody therapeutics and small molecule products for
cancer, autoimmune diseases and inflammatory diseases.
INVESTORS: SOFTBANK CORP. (Lead), BioVision
2/23/2004 10:17:46 AM
9. ANDevices
Raises Funds in First Round [Fremont, CA]
ANDevices is a developer and manufacturer of silica-on-silicon
based planar waveguide products for the communications and biotech
industries.
INVESTORS: AsiaTech Management (Lead), Individuals
2/20/2004 9:21:26 AM
10. Morphotek
Raises $26,000,000 in Series C Round [Exton, PA]
Morphotek is a biotechnology company specializing in the development
of protein and antibody products through the use of a novel and
proprietary gene evolution technology.
INVESTORS: Forward Ventures (Lead), Burrill & Company,
CB Health Ventures, China Development Industrial Bank, DSM Venturing,
Flagship Ventures, Individuals, Morgenthaler Ventures, Rock Maple
Ventures, S.R. One, Trieste Investment Group
2/18/2004 10:51:34 AM
11. Qualyst
Raises Funds in Series A Round [Research Triangle Park, NC]
Qualyst is a developer of technologies for the drug discovery
and development marketplace. The company focuses on technologies
that predict with greater accuracy the disposition of a particular
drug within the human body.
INVESTORS: Undisclosed
2/17/2004 5:10:08 PM
12. Amphora
Discovery Raises $13,000,000 in Third Round [Research Triangle
Park, NC]
Amphora Discovery is a drug discovery company utilizing microfluidic
assay techniques to screen a purified and diverse chemical library
across an array of biological targets.
INVESTORS: 3i Group, ARCH Venture Partners, MPM Capital,
Venrock Associates, Versant Ventures
2/17/2004 4:59:32 PM
13. Acceleron
Pharma Raises $25,000,000 in Series A Round [Cambridge, MA]
Acceleron is a biopharmaceutical company developing drugs for
important unmet medical needs through proprietary approaches that
exploit the therapeutic potential of a large family of growth
and differentiation factors.
INVESTORS: Polaris Venture Partners (Lead), Advanced Technology
Ventures, Flagship Ventures, Sutter Hill Ventures, Venrock Associates
2/13/2004 2:31:42 PM
14. Cryptopharma
Raises $1,600,000 in First Round [Australia]
Cryptopharma is a developer of pro-drugs of novel steroid analogues
for therapeutic use to treat solid tumours and chronic inflammatory
diseases.
INVESTORS: GBS Venture Partners (Lead), Biocomm, UniSeed
2/13/2004 1:40:15 PM
15. Correlogic
Systems Raises Financing [Bethesda, MD]
Correlogic Systems is a clinical proteomics company that has developed
proprietary pattern recognition and pattern discovery software
and laboratory processes with a wide variety of applications for
biomarker discovery, disease detection, and new drug ...
INVESTORS: Mitsui & Co. Venture Partners
2/13/2004 9:17:18 AM
16. immatics
Biotechnologies Raises $9,940,000 in First Round [Germany]
immatics biotechnologies GmbH is an independent biopharmaceutical
company.
INVESTORS: 3i Group, Grazia Equity GmbH, Merifin Capital,
Wellington Partners Venture Capital
2/12/2004 3:12:40 PM
17. Zyomyx
Raises $10,000,000 in Series F Round [Hayward, CA]
Zyomyx is a developer of protein biochips that are used to bridge
the gap between genomic information and protein function.
INVESTORS: CSFB Private Equity (Lead), Alloy Ventures,
Hambrecht & Quist Capital Management, Lilly Ventures, Mediphase
Venture Partners, Singapore Economic Development Board
2/12/2004 10:27:35 AM
18. Kadmus
Pharmaceuticals Raises $15,300,000 in Series A Round
Kadmus Pharmaceuticals is a developer of proprietary molecules
that target critical pathways contributing to pain and other disorders
of the nervous system.
INVESTORS: VenGrowth Capital (Lead), CDP Capital, Gray
Ghost, Sanderling Ventures, Singapore Economic Development Board,
Softbank Capital Partners
2/9/2004 12:34:43 PM
19. Orla
Protein Technologies Raises $513,000 in Second Round [United Kingdom]
Orla Protein Technologies is a bio-nanotechnology company integrating
biological systems and physical devices through engineered protein
interfaces. The company's technology which is based upon self-assembling
membrane protein scaffolds allows large sc...
INVESTORS: Northern Enterprise (NEL)
2/5/2004 11:05:57 AM
20. Trillium
Therapeutics Raises $6,000,000 in Series A Round Add-on [Canada]
Trillium Therapeutics (TTI) is an immune therapy research and
development company, focusing on therapies that restore balance
to the immune system in conditions associated with abnormal and
harmful immune responses, such as autoimmune and inflammatory
...
INVESTORS: Business Development Bank of Canada (BDC) (Lead),
Canadian Medical Discoveries Funds (CMDF), VenGrowth Capital
2/5/2004 10:15:24 AM
21. Repromedix
Raises $1,600,000 [Woburn, MA]
Repromedix is a National Reference Testing Laboratory dealing
primarily in esoteric advanced genetic, hormonal, and immunological
infertility testing.
INVESTORS: Brook Venture Partners, Others
2/2/2004 1:53:02 PM
22. Alimentary
Health Raises $1,600,000 in Seed Financing Round [Ireland]
Alimentary Health is a developer of gastrointestinal (GI) therapeutics.
INVESTORS: Seroba BioVentures (Lead), Enterprise Ireland,
Individuals
1/30/2004 11:42:35 AM
23. Cyclacel
Raises $39,000,000 in Series D Private Placement [United Kingdom]
Cyclacel is a developer of biotechnology and therapeutics for
treating cancer and other serious diseases by exploring the biology
of cell cycle control and rational drug design chemistry.
INVESTORS: BankInvest, Biomedical Sciences Investment Fund,
Carnegie Fund, Finsbury Life Sciences Investment Trust, GeneChem
Management, HBM Partners (HBM BioVentures), INVESCO Private Capital,
Lloyds TSB Development Capital, Merifin Capital, Merlin Biosciences,
...
1/29/2004 11:18:15 AM
24. BioTrove
Raises $10,900,000 in Financing [Woburn, MA]
BioTrove is a developer of micro- and nano-scale engineering solutions
for pharmaceutical drug discovery and biotechnology.
INVESTORS: Biofrontier Partners, Catalyst Health and Technology
Partners, CB Health Ventures, Zero Stage Capital
1/29/2004 10:15:42 AM
25. Hemocellular
Therapeutics Raises $1,000,000 in Seed Financing Round [Chapel
Hill, NC]
Hemocellular Therapeutics is a developer of a platform for molecular
cross-linking of cell membranes to stabilize them for bioengineering
purposes.
INVESTORS: Catalysta Partners (Lead), BD Ventures, Individuals
1/28/2004 4:38:51 PM
26. Saegis
Pharmaceuticals Raises $2,000,000 in Series B Round Add-on [Half
Moon Bay, CA]
Saegis Pharmaceuticals is a pioneer in the development of medicines
that protect and enhance the function of the human mind.
INVESTORS: Stanley Medical Research Institute (Lead)
1/28/2004 10:45:35 AM
27. CureTech
Raises $1,700,000 [Israel]
CureTech is a biotechnology company developing breakthrough monoclonal
antibody-based therapeutics and vaccines for the treatment of
cancer and other immune related diseases. The company's leading
product is a fully humanized monoclonal antibody (mAb) ...
INVESTORS: Clal Biotechnology Industries
1/20/2004 3:16:24 PM
28. Divergence
Raises $4,064,000 [Saint Louis, MO]
Divergence is a research and development company dedicated to
the discovery of effective and ecologically sound strategies for
the control of parasites and other pests. The company's initial
focus is on parasitic nematodes, one of the world's major pes...
INVESTORS: Individuals, Prolog Ventures
1/19/2004 1:59:08 PM
29. Peninsula
Pharmaceuticals Raises $57,900,000 in Series C Round [Alameda,
CA]
Peninsula Pharmaceuticals is a developer of optimal anti-infective
therapies for the treatment of patients with life-threatening
infections.
INVESTORS: A.M. Pappas & Associates, Canaan Partners,
Domain Associates, Montreux Equity Partners
1/16/2004 1:09:03 PM
30. SurgRx
Raises $5,000,000 in Second Round [Palo Alto, CA]
SurgRx is a developer of proprietary technology for tissue sealing
and cutting, to be used in surgical procedures.
INVESTORS: California Technology Ventures, Individuals
1/16/2004 11:13:36 AM
31. WaferGen
Raises $500,000 in Seed Financing Round [Fremont, CA]
WaferGen is a developer of silicon chips for high throughput screening
in drug discovery.
INVESTORS: Global Asset Capital (Lead)
1/15/2004 11:35:40 AM
32. Pulmonx
Raises $7,000,000 in Series A Round [Palo Alto, CA]
Pulmonx is a developer of technology for minimally invasive lung
procedures.
INVESTORS: MedVenture Associates, Montreux Equity Partners
1/15/2004 9:32:37 AM
33. TargeGen
Raises $30,000,000 in Second Round [San Diego, CA]
TargeGen is a developer of novel therapeutics to treat cancer
and ischemic disease (stroke, heart attack) by regulating the
processes associated with new blood vessel formation (angiogenesis)
and vascular permeability.
INVESTORS: CDP Capital-Technology Ventures (CDP Sofinov),
China Development Industrial Bank, Enterprise Partners, Forward
Ventures, William Blair Capital Partners
1/14/2004 4:47:56 PM
34. Enanta
Pharmaceuticals Raises $12,000,000 in Financing [Watertown, MA]
Enanta Pharmaceuticals is a developer of small-molecule drugs
by using chemistry technology and transforming existing drugs,
natural products, and biologically active peptides.
INVESTORS: Advent International, BioVentures Investors,
NIB Capital Private Equity, Oxford Bioscience Partners, Swiss
Life Private Equity Partners, Techno Venture Management, Yasuda
Enterprise Development
1/14/2004 3:32:07 PM
35. Synta
Pharmaceuticals Raises $50,000,000 in Financing [Lexington, MA]
Synta Pharmaceuticals is an emerging pharmaceutical company focused
on discovering, developing, and commercializing breakthrough products
for severe medical conditions.
INVESTORS: AIG SunAmerica
1/14/2004 1:54:37 PM
36. Exagen
Diagnostics Raises $5,400,000 in Series A Round [Albuquerque,
NM]
Exagen Diagnostics is a developer of molecular diagnostics technology.
INVESTORS: Tullis-Dickerson & Co. (Lead), vSpring Capital,
Wasatch Ventures
1/14/2004 10:47:18 AM
37. Proteus
Biomedical Raises $5,300,000 in Series B Round [Menlo Park, CA]
Proteus Biomedical is a developer of proprietary MEMS-based sensor
products focused on improving the treatment and management of
congestive heart failure patients.
INVESTORS: Adams Street Partners (Lead), Asset Management
Company, Fletcher Spaght Ventures, Spring Ridge Ventures
1/14/2004 9:25:40 AM
38. Vascular
Biogenics Raises $5,000,000 in Financing [Israel]
Vascular Biogenics is a developer of drug treatments for vascular
conditions.
INVESTORS: Teva Pharmaceuticals (Lead)
1/13/2004 9:49:36 AM
39. OyaGen
Raises Seed Financing Round [Rochester, NY]
OyaGen is a developer of a class of HIV drugs that may enable
the body's own immune system to halt an HIV infection.
INVESTORS: Trillium Group (Lead)
1/12/2004 4:39:37 PM
40. Metabolex
Raises $4,000,000 in Sixth Round Add-on [Hayward, CA]
Metabolex is a developer of therapeutics for type 2 diabetes.
INVESTORS: Birchmere Ventures, CIBC World Markets, Merlin
Biosciences
1/12/2004 12:19:34 PM
41. Hydra
Biosciences Raises $18,875,000 in Series B Round [Cambridge, MA]
Hydra Biosciences is a developer of molecular regeneration medicines,
cardiovascular therapies and drugs targeting ion channels.
INVESTORS: Lilly Bioventures (Lead), Abbott Laboratories,
Abingworth Management, Advanced Technology Ventures, BioVentures
Investors, Boston Medical Technologies, New Enterprise Associates
(NEA), Polaris Venture Partners
1/12/2004 12:08:23 PM
42. Concurrent
Pharmaceuticals Raises $15,000,000 in Series B Round [Fort Washington,
PA]
Concurrent Pharmaceuticals is a developer of an integrated technology
platform that will enable the de-novo design of bioactive molecules
"in silico."
INVESTORS: Intel Capital, New Enterprise Associates (NEA),
Prospect Venture Partners, Venrock Associates
1/12/2004 11:08:49 AM
43. Threshold
Pharmaceuticals Raises $41,000,000 in Series B Round [South San
Francisco, CA]
Threshold Pharmaceuticals is a developer of novel therapeutics
to target metabolic pathways for application in the field of oncology.
INVESTORS: Morgenthaler Ventures (Lead), CHL Medical Partners,
Pequot Ventures, ProQuest Investments, Sofinnova Ventures, Sutter
Hill Ventures, Three Arch Partners
1/12/2004 10:39:42 AM
44. Athenix
Raises $12,520,000 in Series B Round [Durham, NC]
Athenix is a provider of genes, proteins, traits, and transgenic
organisms for multiple industry sectors including agricultural
chemicals, specialty chemicals, seed, industrial enzymes, feed,
and energy. The company's core technology platform is center...
INVESTORS: Hunt Ventures, Intersouth Partners, Polaris
Venture Partners
1/9/2004 11:13:37 AM
45. Vivant
Medical Raises $6,500,000 [Mountain View, CA]
Vivant Medical is a developer of novel and proprietary microwave
ablation technology for the minimally invasive treatment of benign
and cancerous solid tumors. The company's VivaWave Ablation System
has been designed to provide larger, faster ablations...
INVESTORS: California Technology Ventures (Lead), Adams
Street Partners, Individuals, Johnson & Johnson, Pacific Venture
Group, Three Arch Partners
1/9/2004 10:37:54 AM
46. Cellomics
Raises $5,300,000 [Pittsburgh, PA]
Cellomics is a company founded on the principles of cellomics,
dedicated to providing all the tools required to generate and
use cellular knowledge in the life sciences market.
INVESTORS: Alta Partners, Axiom Venture Partners, Burrill
& Company, Carl Zeiss, ck-capital, InterWest Partners, Oxford
Bioscience Partners, Vector Fund Management
1/9/2004 10:07:38 AM
47. Pyxant
Labs Raises $500,000 [Colorado Springs, CO]
Pyxant Labs is a contract research laboratory specializing in
GLP bioanalytical chemistry support for life sciences clients.
The company has experience with >400 compounds on >100 matrices
during 16 years of practice.
INVESTORS: Murphree Colorado CAPCO
1/7/2004 12:27:41 PM
48. Galileo
Genomics Raises $8,700,000 [Canada]
Galileo Genomics is a next-generation genomics company dedicated
to the discovery of GeneMaps, genes, and biomarkers associated
with the root cause of common diseases and drug response.
INVESTORS: Bio Fund, HBM Partners (HBM BioVentures), Others
1/7/2004 11:18:54 AM
49. Lipomics
Technologies Raises $2,100,000 in Series C Round [West Sacramento,
CA]
Lipomics Technologies is a provider of analysis and interpretation
of lipid metabolites for discovery of drug targets and diagnostic
markers.
INVESTORS: DFJ Frontier Fund (Lead), Individuals
1/6/2004 5:00:21 PM
50. NsGene
Raises $3,000,000 in Second Round [Denmark]
NsGene is a developer of novel cell and gene based products for
the treatment of neurological diseases. The company concentrates
on developing treatments that are based on neural transplantation
of naked or encapsulated cells or vectors capable of tran...
INVESTORS: Dansk Erhvervsinvestering, Dansk Kapitalanlaeg,
Individuals, LD Pensions, Others
1/5/2004 11:52:21 AM
51. ZGene
Raises $2,500,000 [Denmark]
ZGene is a developer of technology that enhances the effect of
anti-cancer drugs by reducing their toxicity. The systems is based
on enzymes, which are able to increase the activation of anti-cancer
drugs in tumor cells with a more rapid killing of can...
INVESTORS: Dansk Erhvervsinvestering, Symbion Capital
1/5/2004 11:12:33 AM
52. ViaCell
Raises $20,000,000 in Financing [Boston, MA]
ViaCell is a fully-integrated cellular medicine company engaged
in research and development of cellular therapy products for the
treatment of numerous life-threatening or debilitating diseases
for which current therapy options are inadequate or non-exi...
INVESTORS: Amgen (Lead)
1/2/2004 10:23:48 AM
53. Bioventis
Raises $2,250,000 in Seed Financing Round [Austria]
Bioventis is a developer of an antigen identification program
that can be used for the development of novel antibiotics.
INVESTORS: Undisclosed (Lead)
1/2/2004 10:06:09 AM
54. Sophion
Bioscience Raises $4,200,000 in Third Round [Denmark]
Sophion Bioscience is a manufacturer of screening equipment for
drug discovery.
INVESTORS: Dansk Erhvervsinvestering, Dansk Kapitalanlaeg,
Scandinavian Life Science Venture, VaekstFonden
12/31/2003 10:21:22 AM
